Call the Department of Gastroenterology: 617-726-2426
Explore This Treatment
Overview
This year over 50,000 men and women in the U.S. will die from colon cancer. And many could have been saved. When colon cancer is detected early, there is a 90% survival rate. When it's not, that number is less than 50%. Starting at age 50, you should have a colonoscopy at least once every ten years to screen for polyps and cancer. Colon cancer can be beaten. Prevention and early detection are your best weapons.
We offer the most advanced colon cancer screenings and treatments available. Our world-renowned specialists can provide the comprehensive care and peace of mind you'll only find at one of the world's leading hospitals.
Talk to your doctor about scheduling your colorectal cancer screening at Massachusetts General Hospital. Then call (617) 726-2426 or request an appointment online.
Please visit our doctors page for a list of our gastroenterologists.
Other Options for Colorectal Cancer Screening
Understanding the different CRC screening options, including home-based stool tests and colonoscopy, depends on the individual risk of colon cancer and the patient’s preferences. Patients can explore and compare the benefits, harms, and risks of each option as they make an informed decision about what matters most to them.
The below sheet describes three screening options that are reasonable for most people: schedule a colonoscopy, have a stool-based test, or delay your colonoscopy for a year.
Colorectal Cancer Screening Shared-Decision Worksheet English | Español
Colonoscopy Risks and Benefits
A colonoscopy is a procedure that involves an examination of the entire colon and requires bowel preparation and sedation. Watch this video to learn about the purpose and benefits of the exam, how the colonoscopy procedure is performed, and the potential risks and complications.
Although disparities in consistent ART use between Black and White Medicare beneficiaries have narrowed since 2013, the percentage of beneficiaries who filled ART prescriptions for 10+ months/year remained significantly lower among Black beneficiaries relative to White beneficiaries in 2019.
Mass General-led phase 2 clinical trial generates promising results for brigatinib as a treatment for the genetic condition, which is characterized by brain and nerve sheath tumors.
MGH’s Age Positively Program, a partnership between the Geriatric Medicine and Infectious Diseases divisions, provides care and resources to enhance the care and well-being of people with HIV as they age.
Immune activation in a pregnant woman can occur in response to metabolic diseases like obesity, infections in pregnancy, exposure to pollution and environmental toxins, or even stress and can have negative effects on fetal brain immune cells (microglia).